Thrombotic Thrombocytopenic Purpura Sequelae

An ASH ’25 summary by Dr. Wolfgang Miesbach: iTTP remission ≠ cure–the vascular injury persists. TTP as a cardiovascular disease equivalent. I just finished Dr. Senthil Sukumar’s session on long-term iTTP management. This completely changed how I think about these patients, as illustrated: 28.6% of survivors → major cardiovascular events 50% → silent cerebral infarcts (vs […]

Comments (0)

Thrombophilia

Dec 11 2025

george

Anesthesiologists’ Approach to Perioperative Bleeding Management

ASH ’25 Report from Dr. Wolfgang Miesbach: Perioperative Bleeding Management: What 1,030+ U.S. Anesthesiologists Think About Current Challenges 50.6% practiced primarily at academic medical centers, while 42.3% worked in community hospitals, with additional representation from military/VA hospitals (3.7%). Nearly half (48.4%) worked at Level I trauma centers. The Progress… Prothrombin complex concentrates (PCCs) have become […]

Bleeding Disorders

Hemophilia Rx: “Paradox of Choice”

An ASH ’25 report from Dr. Wolfgang Miesbach: The “Paradox of Choice” is very real in Haemophilia right now. I just caught Dr. Mark Reding’s insightful presentation at ASH25, and it really highlighted that having more options doesn’t actually make the decision easier. In fact, it makes it harder. We’re looking at a massive toolkit […]

Bleeding Disorders

Associations of FVIII & FIX Levels with CVD and CVD Mortality

Go to your medical library to access this provocative journal article: Harris K, Woodward M, Folsom AR, et al. Associations between plasma levels of coagulation factors VIII and IX and incident cardiovascular disease and mortality: systematic review and meta-analysis. J Thromb Haemost. 2025:S1538-7836(25)00598-7. doi: 10.1016/j.jtha.2025.09.008. PMID: 41038279. Abstract Background: Associations of plasma levels of coagulation […]

Arterial Thrombosis

Diagnostic Equity Case: Varying INR

This question came from a patient to the Diagnostic Equity Service on 12-9-2025: I notice my INR keeps changing even though I take the same warfarin dose. Could this be a lab issue or a metabolism issue? Thank you for what you do. Abby Carroll, MS, MLS (ASCP)cm answered: In most cases, INR variability is […]

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

Asundexian Anti-XIa Antithrombotic Shows Promise

Select “Bayer’s Asundexian anti XIa antithrombin met primary efficacy and safety endpoints in a landmark phase III OCEANIC-STROKE study for secondary stroke prevention” for their press release presented at ASH 2025.

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]

Comments (1)

Anticoagulant Therapy

Dec 8 2025

george

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

David Kuter gave this presentation at ASH 2025: Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression. Increase Platelet Production The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct […]

Bleeding Disorders

Let’s Update Hemostasis Test Names

Here is a provocative recommendation from colleague and friend, Dan Kaczor: Hi George, This is the follow-up on the issue of nomenclature posted on 12-1-2025. Although there may be reasons to consider change, as pointed out in the examples given, I believe that we are moving in the wrong direction and are making things difficult […]

Validation

November 2025 QQ Summary: Historic Coag Factor Nomenclature

Our November Quick Question summary about Stuart-Prower Factor, linked to a 2023 article by Dave McGlasson about coagulation factor nomenclature. The summary and McGlasson’s article attracted a comment from Dr. Emmanuel Favaloro, which described the nomenclature of traditional and current VWF activity assays. Dr. Favaloro cited three open-access articles on this topic (click to obtain the […]

Comments (0)

Blog

All Posts

Thrombotic Thrombocytopenic Purpura Sequelae

Anesthesiologists’ Approach to Perioperative Bleeding Management

Hemophilia Rx: “Paradox of Choice”

Associations of FVIII & FIX Levels with CVD and CVD Mortality

Diagnostic Equity Case: Varying INR

Asundexian Anti-XIa Antithrombotic Shows Promise

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

Let’s Update Hemostasis Test Names

November 2025 QQ Summary: Historic Coag Factor Nomenclature

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question